Cambrex is expanding its solid form screening and crystallisation process development facility in Edinburgh, Scotland. The expansion will double the current footprint to 15,000 sqft.
The Scottish site currently has 50 employees and the expansion will add additional laboratory space to enable the recruitment of up to 40 more scientists, with the potential for further growth in the future.
Fit-out is expected to begin in late August 2019 with a target completion date of the end of the year.
The CDMO’s Edinburgh site is competitive in providing solid form development services for drug substance and drug product. These include solid-state investigations such as salt, co-crystal and polymorph screening, in addition to crystallisation process development and GMP analytical services.
The expanded laboratory space will allow the installation of additional instruments and reactors for larger-scale crystallisation studies and solid form screening capabilities. Plans are in place for the installation of new ultra-performance liquid chromatography (UPLC) and gas chromatography instruments, as well as additional process analytical technology (PAT) tools.
“This strategic expansion, the increase in headcount and the investment in new equipment will enable us to serve more customers in the solid-state screening market,” said Mark Benger, Edinburgh Site Director for Cambrex. “We have increasingly been asked by clients for additional services such as larger-scale crystallisation and we will now be able to provide these as well as adding greater efficiency and capacity at the Edinburgh site,” he explained.
Edinburgh became part of Cambrex’s global network of development and manufacturing facilities after the acquisition of Avista Pharma Solutions earlier this year. The facility was formerly known as Solid Form Solutions, an industry leader in solid-state services, prior to the acquisition.
